Biokin Pharmaceutical is a biomedical enterprise focused on the global biomedical frontier, committed to addressing unmet clinical needs. It possesses full-series drug research and development capabilities encompassing small-molecule chemical drugs, large-molecule biologics, and ADC drugs. With integrated advantages ranging from intermediates, active pharmaceutical ingredients (APIs), to formulations, it covers the entire lifecycle from "R&D to Production to Marketing", offering comprehensive commercialization capabilities。

The company has R&D centers in both China and the United States: SystImmune in Seattle, Baili-Bio/Baili Pharmaceutical, and four production bases: Guorui Base (for injectables and oral formulations), Baili Base (for oral solid formulations and lyophilized injectables), Hiatt/Jingxi Base (for intermediates and chemical APIs), and Baili-Bio Base (for innovative drugs)。